Continuous manufacturing of LNPs and other types of nanoparticles is the future of pharmaceutical manufacturing. Adoption of new technologies and real-time testing strategies will position the pharmaceutical industry to overcome current challenges, leading to higher quality drug products. The recent global pandemic highlighted the need for vaccines and other drug products that need to be manufactured fast, efficaciously, and have a global reach.

As a result, we have seen a rapid growth in new clinical modalities using mRNA technologies that are poised to be the future of medicine. Being able to produce customized, targeted drug products, that are individually designed for a particular patient will further have a significant impact on new treatment strategies. DIANT’s innovative technology offers a solution for continuous manufacturing process. Over the years DIANT’s team has been working on developing systems that can provide a scalable, turnkey solution from R&D to commercial manufacturing.

In this webinar you’ll learn:

• Advantages of using closed end to end continuous manufacturing process v. traditional batch process
• DIANT provides a turnkey solution for continuous manufacturing of different types of nanoparticles
• DIANT offers a variety of systems starting from a benchtop R&D system (DIANT LARU) to a high-throughput GMP-ready system (DIANT LIFT)

• Research Scientists
• Product development Scientists and Engineers
• Stakeholders in Manufacturing
• Stakeholders in Business Development